



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 13th November 2020
Ein Cyf / Our Ref: 20-J-040

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk



Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

Dear ,

I refer to your Freedom of Information Act Request acknowledged by ourselves on 20th October 2020. Your request sought information relating to head and neck cancer.

The data below represents the period 1st July to 30th September 2020.

1. Within your health board, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?

- **Total squamous cell carcinoma** - 9
- **Locally advanced** - <5*
- **Recurrent and/or metastatic** - <5* (data held centrally will only be new presentations of head and neck cancer.)

2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?

See question 1

3. Within your health board, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

- **Carboplatin (monotherapy or in combination with 5-FU)** - 6
- **Cisplatin (monotherapy or in combination with 5-FU)** - 7



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **Cetuximab with/without chemotherapy** - 0
- **Cetuximab with radiotherapy** - 0
- **Pembrolizumab monotherapy** - 0
- **Pembrolizumab with chemotherapy** - 0
- **Nivolumab** - 7
- **Docetaxel (monotherapy or in combination with 5-FU)** - 0
- **Fluorouracil (5FU)** - 0
- **Radiotherapy only** - 13
- **Other** - not applicable

4. Within your health board, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- **Sunitinib** - 5
- **Avelumab + Axitinib** - 0
- **Axinitib** - <5*
- **Cabozantinib** - 15
- **Everolimus** - 0
- **Lenvantinib + Everolimus** - 6
- **Nivolumab** - 16
- **Nivolumab + Ipilimumab** - <5*
- **Pazopanib** - 21
- **Pembrolizumab + Axitinib** - 0
- **Temsirolimus** - 0
- **Tivozanib** - 10
- **Other** - Not applicable

5. Does your health board participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Currently Swansea Bay Health Board is participating in one clinical trial for the treatment of head and neck cancer.

CompARE: Phase III randomised controlled trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
9 patients recruited to trial

6. Does your health board participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

Currently Swansea Bay Health Board is not participating in any clinical trials for the treatment of renal cell carcinoma.

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This



exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

